Jefferies Healthcare Conference
|
|
- Albert Ellis
- 6 years ago
- Views:
Transcription
1 0 Jefferies Healthcare Conference 3 June 2015 NASDAQ: CRIS
2 Forward Looking & Other Important Cautionary Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of These forward-looking statements include, among others, statements about our business, plans, prospects and strategies. The words anticipates, believes, estimates, expects, intends,, may, plans, projects, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Important factors that may cause or contribute to such differences include the factors set forth under the caption Risk Factors in our Quarterly Report on Form 10-Q for the period ended March 31, 2015 and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission ( SEC ). The forward-looking statements included in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so except as required by law. 1
3 Curis Leading biotech company that effectively develops and expects to commercialize oncology drugs for significant patient benefit and access Small molecule antagonists of immune checkpoints Aurigene Multiple small molecule programs targeting checkpoint receptor-ligand interactions ongoing PDL1, orally available small molecule disrupts PDL1/PD1 interaction: IND filing expected in 2015 Drug candidates to address hematologic cancers CUDC-907, clinical activity in diffuse large B cell lymphoma: Phase 2 expected in Q IRAK4, orally available small molecule inhibitor: IND filing expected Q Erivedge for advanced basal cell carcinoma Roche/Genentech Approved in the US, EU and multiple other countries worldwide, royalty revenues to Curis Development in idiopathic pulmonary fibrosis planned 2
4 Pipeline: Novel, Targeted Cancer Therapeutics Advancing key proprietary programs Program Target Indication Preclinical Phase 1 Phase 2 Phase 3 Market Key Proprietary Programs CUDC-907 HDAC/PI3K DLBCL Phase 1 Expansion Breast Cancer & NUT Midline Carcin. Phase 1 PD-L1i* PD-L1 Multiple cancers Pre-IND IRAK4i* IRAK4 DLBCL Waldenstrom s macroglobulinemia Pre-IND Partnered Program Erivedge Hedgehog Advanced Basal Cell Carcinoma Idiopathic Pulmonary Fibrosis (IPF) Phase 2** Approved in > 50 Countries Phase Phase 1/22 Other Proprietary Programs CUDC-427 IAP Lymphoma Phase 1 CUDC-305 Hsp90 Cancers Phase 1 Phase 1b/2 * Subject to Curis expectations to exercise options to exclusively license the Development Candidates from each program ** IND filed in June, No patients enrolled; recruitment suspended pending modification of trial design. 3
5 CUDC-907 Potent HDAC and PI3K enzyme inhibition in one oral small molecule High tissue distribution significant levels of enzyme inhibition activity Active in patients with DLBCL, including transformed follicular DLBCL HDACi PI3Ki IC50 (nm) HDAC PI3K Enzyme Alpha Delta Beta Gamma IC50 (nm)
6 CUDC-907 in Hematologic Cancer Phase 1 trial completed 57 patients with relapsed/refractory lymphoma and multiple myeloma 40 patients in dose escalation, 17 patients in expansion cohorts (DLBCL, HL, MM) Recommended Phase 2 dose and schedule determined 60mg daily dose administered 5 days on / 2 days off; 21-day treatment cycles PK and PD demonstrate drug exposure and target engagement High levels of drug exposure in tumor tissue vs. plasma HDAC and PI3K enzyme modulation observed in patient PBMC samples Safe and tolerable at recommended dose Most frequent AEs ( 2 patients): diarrhea, fatigue, thrombocytopenia DLTs of diarrhea and hyperglycemia Clinical benefit merits continued development Objective responses in patients with DLBCL and Hodgkin s lymphoma Stable disease in patients with Hodgkin s lymphoma and multiple myeloma 5
7 CUDC-907 PK Profile CUDC-907 rapidly distributes to tissues including tumor Preclinical PK Profile Balb/c Mice Clinical PK Profile 5/2 Schedule, 60mg dose: Plasma & Tumor PK TUMOR TISSUE PLASMA PLASMA 6
8 Overall Activity in Patients with Lymphoma * 7
9 Clinical Benefit in Patients with DLBCL 16 patients with DLBCL enrolled, 10 evaluable for response Effective disease control, including partial and complete responses Noteworthy benefit in patients with transformed DLBCL Time to Response and Durability (days) Max Tumor Regression (%) Ongoing Ongoing Ongoing Ongoing, proceeded to ASCT Days
10 Case Report Patient with RR t-fl/dlbcl Subject ID Tumor Type Age/Gender Response to CUDC-907 t-fl/dlbcl 71 / Male PR (Cycle 10) CR (Cycle 12) Duration on CUDC Days + Treatment Status Ongoing Prior Treatment Best Response 1. R-CHOP 2011 CR 2. R-ICE 2012 PR 3. ASCT 2012 CR Baseline PET/CT Cycle 10 PET/CT (-52%) 9
11 CUDC-907 in Diffuse Large B-cell Lymphoma Phase 1 dose escalation completed, expansion in DLBCL ongoing Monotherapy and combination with rituximab arms open Recommended Phase 2 dose and schedule determined 60mg dose on 5/2 schedule Safe and tolerable: manageable diarrhea, fatigue and thrombocytopenia Novel tissue distribution profile: high drug exposure Orphan drug designation for DLBCL granted by FDA Planned end-of-study meeting request with the FDA Registration-directed trial opportunity in relapsed/refractory disease Phase 2 monotherapy trial in patients with transformed DLBCL Phase 2 randomized trial in combination with rituximab Earliest trial start date in Q
12 Curis Immuno-oncology Strategy Small molecule antagonists of checkpoint receptor-ligand interactions Up to five years exclusive partnership with Aurigene Sequences from interaction interface High affinity peptides PD1/PDL1 receptor-ligand interaction Truncation & modification Structure-based design: small molecule antagonists generated based on interface of receptor-ligand interaction Small molecule library Identify small molecule candidate 11
13 Ability to Optimize Potency and Desired Selectivity Biology Disease Discovery PDL1 TIM3 LAG3 VISTA 12
14 PD-L1 Antagonist Properties Disrupts interaction of both mouse and human PD1/PD-L1 Potent antagonism of PD-L1 mediated inhibition of T lymphocytes EC50 ~15 nm for rescue of lymphocyte proliferation EC50 ~20 nm for INF-γ production Excellent drug-like properties with oral bioavailability of ~50% Excellent expected safety profile No interaction with CYP enzymes No alteration of herg activity Clean in receptor and enzyme panels No adverse events observed 14-day high dose administration in mice 13
15 PD-L1 Antagonist In vivo PD Profile Circulating INF-γ production in mice after oral administration Lead candidate (mg/kg) J43 anti-mouse PD1 antibody 14
16 PD-L1 Antagonist Properties In vivo activity profile Average metastatic counts B16 melanoma model Average metastatic counts 73% reduction in metastasis p<0.05 Metastasis counts in Individual animals p< Vehicle LC, 10mpk PO Vehicle LC, 10mpk PO In vivo Efficacy (MC38 Model) p<0.05 p<0.01 LC: Lead Candidate J43 anti-mouse PD1 antibody 15
17 PD-L1 Antagonist Properties 14 day repeat dose safety profile mouse Mortality : No mortality Clinical Signs of Toxicity : No abnormalities detected Body weight : No test item related changes Food Consumption : No test item related changes Hematology : No test item related changes Clinical Chemistry : No test item related changes Gross Pathology : No treatment related changes Organ weights : No treatment related changes Histopathology : No treatment related changes 16
18 PD-L1 Small Molecule Antagonist Selectively binds to target immune checkpoint ligand (PD-L1) and potently disrupts interaction with receptor (PD1) Induces proliferation of T-cells and IFN-gamma production Clean off-target profile (enzyme, receptors, ion channels, kinases) Orally bioavailable with good PK properties in mice Clean preliminary in vivo safety profile Induces IFN-gamma production in vivo after oral administration Anti-tumor activity in multiple syngeneic tumor models In preparation for GLP toxicology studies IND filing expected in Q4,
19 IRAK4 - A Target for Cancer Therapy Toll and IL-1 receptor signaling pathway implicated in certain cancers MYD88 adaptor protein transduces receptor signaling to IRAK4 IRAK4 kinase activity, through IRAK1 is critical for NF-κB activation Activating MyD88 Mutations in human cancer ~30% in ABC-DLBCL, ~90% in Waldenstrom's macroglobulinemia, ~5-10% in CLL IL-1R TLRs Cytokines Plasma membrane MYD88 IRAK4 IRAK1 PO 4 p50 NF-κB p65 Nucleus Survival 18
20 Lead Molecules are Active In Vivo Cancer and inflammatory disease models Active in in vivo oncology and inflammatory disease models LC = Lead Candidate IRAK4 inhibitor Lef = Leflunomide Thyop = Theyophilline, IP administration 19
21 Lead IRAK4 Small Molecule Inhibitors Potent and selective inhibitors of IRAK4: biochemical IC 50 in low nm Potent cell-based activity and readouts Inhibit IRAK1 phosphorylation in cell-based assays Inhibit TNF-α production in human PBMC Inhibit proliferation of DLBCL cell lines with MYD88 mutation in culture Orally bioavailable with excellent PK properties drug-like molecules Effective in vivo anti-tumor activity mutant DLBCL model Active in in vivo inflammatory disease models arthritis Safety studies ongoing IND filing expected in Q1,
22 Erivedge - Expanding Revenue Opportunity Developed under Genentech and Roche collaboration Erivedge (vismodegib) Oral inhibitor of Hedgehog signaling pathway Approved for treatment of advanced basal cell carcinoma (2012) Milestone and royalty-based revenue stream for Curis Global net sales: continued year-over-year growth ~ $30 million in launch year (2012) net sales recorded by Genentech and Roche ~ $80 million in 2013 ~$136 million in 2014 Royalty revenue to Curis $6.8 million in 2014 royalties to Curis through December 31, 2014 $59 million in milestones earned Other development by Genentech and Roche IND filed for Idiopathic Pulmonary Fibrosis: June 2014 Roche indicated potential trial initiation with amended protocol 21
23 Expected 2015 Milestones CUDC-907 Ongoing study in patients with transformed DLBCL as monotherapy Ongoing study in combination with rituximab Ongoing Phase 1 study in patients with solid tumors interim data in Q Initiation of Phase 2, registration-directed trial in Q Preclinical assessment of activity in combination with immune checkpoint inhibitors PD-L1 antagonist oral small molecule immuno-oncology candidate IND filing Q IRAK4 inhibitor oral small molecule Development candidate(s) Q IND filing Q
24 Summary Financial Data March 31, 2015 (000 s) Cash, cash equivalents, investments $ 107,200 Erivedge secured debt (non-recourse to Curis) $ 27,400 Basic shares outstanding 128,300 Fully-diluted shares outstanding* 141,000 Net loss $ (18,729) * - Difference between fully-diluted and basic shares outstanding is comprised solely of options to purchase common stock. 23
25 NASDAQ: CRIS 24
Corporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationCORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER
CORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER March 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements
More informationME-401: A Highly Differentiated PI3Kd- Selective Inhibitor
NASDAQ: MEIP ME-401: A Highly Differentiated PI3Kd- Selective Inhibitor June 2017 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationCorporate Presentation. April 2016
Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More informationNanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management Outline Introduction The Nanoscale Applications Realization of a Vision There s Plenty
More informationComparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017
Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationGood morning and thank you for joining us for our quarterly update.
Q1 2018 Earnings Conference Call May 7, 2018 11:00 AM ET Introduction and Forward Looking Statements in APPENDIX I Garo Armen Good morning and thank you for joining us for our quarterly update. We have
More informationPreclinical Development of Biologics: Case-by-case, so get off of my case!
Preclinical Development of Biologics: Case-by-case, so get off of my case! Northeast Chapter SOT David Jacobson-Kram, Ph.D., DABT Office of New Drugs Center for Drug Evaluation and Research FDA October
More informationThe tetravalent bispecific NK-cell engaging antibody AFM13 (CD30/CD16A) engages and primes innate immune cells for anti-cancer immunity
The tetravalent bispecific NK-cell engaging antibody AFM13 (CD30/CD16A) engages and primes innate immune cells for anti-cancer immunity Martin Treder, PhD Affimed GmbH AACR Annual Meeting 2017 Forward-looking
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationSamatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection
Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Douglas Mayers, MD December 11, 2013 1 Idenix: Advancing All-Oral, Pan-Genotypic Combination
More informationCreating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD
Creating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD CSO Mersana Therapeutics VC-backed Biotech in Cambridge, MA Investors: NEA, Pfizer, Fidelity,
More informationAbGn-107, an ADC Targets Gastrointestinal Tumors
AbGn-107, an ADC Targets Gastrointestinal Tumors For a Healthier Life Presented by Ron Lin Feb. 22, 2016 All Rights reserved AbGenomics International Inc. 4966 El Camino Real, Suite 200, Los Altos, CA
More informationTITLE: Novel Small-Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus
AWARD NUMBER: W81XWH-16-1-0609 TITLE: Novel Small-Molecule Inhibitor of Tyk2: Lucrative Therapeutic Target in Lupus PRINCIPAL INVESTIGATOR: Abhishek Trigunaite CONTRACTING ORGANIZATION: SRI International
More informationFirst-in-Class Bispecific Antibodies For Cancer Immunotherapy
First-in-Class Bispecific Antibodies For Cancer Immunotherapy 2015 Company Highlights Vision Team Platform Pipeline Partners To dominate the bispecific antibody space in immunooncology through unique pipeline
More informationDiscovery and Development of Highly Selective and Orally Bioavailable Macrocyclic IDO-1 Inhibitors
Discovery and Development of Highly Selective and Orally Bioavailable Macrocyclic IDO-1 Inhibitors 1 Tim Briggs Senior Director, Medicinal Chemistry Ensemble Therapeutics Corp. Ensemble Therapeutics Corp.
More informationH.P. Grimm (1), F. Crameri (1), H. Hinton (2), D. Türck (1), H. Silber Baumann (1), B. Ribba (1)
Intricate PK and PD for the novel immunocytokine CEA-IL2v and their pre-clinical to clinical translation H.P. Grimm (1), F. Crameri (1), H. Hinton (2), D. Türck (1), H. Silber Baumann (1), B. Ribba (1)
More informationFDA Perspective on the Preclinical Development of Cancer Vaccines
FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationDEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS
DEVELOPING FIRST-IN-CLASS TREATMENTS IN HAEMATOLOGIC CANCERS DEUTSCHE BANK 42ND ANNUAL HEALTH CARE CONFERENCE MAY 4, 2017 LUIGI COSTA, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationGSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking
More informationPolicy Issues in the Clinical Development and Use of Immunotherapy for Cancer
Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Cancer Immunotherapy Development 2014/2015 Approval of 2 anti-pd-1 antibodies for advanced melanoma and lung cancer http://www.fightcancerwithimmunotherapy.com
More informationNew Hope For Serious Infections
New Hope For Serious Infections Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationAdvancing New Treatments for DMD and C. difficile Infection
Advancing New Treatments for DMD and C. difficile Infection 34 th Annual Canaccord Genuity Growth Conference August 13, 2014 Legal Disclaimer FORWARD-LOOKING STATEMENTS This Document contains forward-looking
More informationInnovative Partnerships in Biotechnology A Biotech Perspective on Past, Present & Future
Innovative Partnerships in Biotechnology A Biotech Perspective on Past, Present & Future Donald Olds Chief Operating Officer & CFO Aegera Therapeutics Inc. June 8, 2010 1 Discussion Points Why do biotech
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): Modulating immune checkpoint pathways like CTLA-4 and PD-1 for cancer immunotherapy has gained much attention in recent years due to their immense
More informationOPT-302: a VEGF-C/VEGF-D Trap for wet AMD
OPT-302: a VEGF-C/VEGF-D Trap for wet AMD Ophthalmology Innovation Summit, Nov 12 2015 Circadian Technologies (ASX:CIR, OTCQX:CKDXY) Megan Baldwin PhD, CEO & MD megan.baldwin@opthea.com 2 Disclaimer Investment
More informationInventiva: acceleration of the clinical development activities and consolidation PRESS RELEASE of the financial position in 2016
COMMUNIQUE DE PRESSE Inventiva: acceleration of the clinical development activities and consolidation PRESS RELEASE of the financial position in 2016 Launch of IVA337 Phase IIb trial in NASH Initiation
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationQ4 and Full Year 2017 Conference Call. February 22, 2018
Q4 and Full Year 2017 Conference Call February 22, 2018 Agenda Welcome McDavid Stilwell VP, Corporate Communications and Investor Relations Q4 2017 and Full Year Review and Recent Highlights Dr. Sandy
More informationFile no./drug Name Name of firm/ Institute Recommendations. M/s. AstrazenecaPharma India Limited
Recommendations: I agree the minutes of 51 st SEC-Oncology & Haematology meeting held on 21.03.2017 at CDSCO HQ New Delhi Agenda File /Drug Name Name of firm/ Institute Recommendations New Drugs Division
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationManagement Discussion and Analysis for the Second quarter of FY
Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion
More informationPreclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator
S830 Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator Yue Chen, Raj Nagaraja, Kha Le, Penelope A Kosinski, Gavin Histen, Charles Kung, Hyeryun Kim, Chandra
More informationUnique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations. [mabs -monoclonal antibodies ] Peter Lloyd
Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations [mabs -monoclonal antibodies ] Peter Lloyd Head of Pharmacokinetics-Pharmacodynamics Novartis Biologics
More informationRoche Committed to Innovation. Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008
Roche Committed to Innovation Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008 This presentation contains certain forward-looking statements. These forward-looking statements
More informationNext-Generation Cancer Therapeutics. June 2015
Next-Generation Cancer Therapeutics June 2015 1 Forward Looking Statements NASDAQ: SRNE Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the Company
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationForward-looking statements
March 2017 Forward-looking statements This presentation contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including the factors described under
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationRegulatory Perspective
Regulatory Perspective Presented by Dr Maria Isaac MASc, MD, PhD, Pharmaceutical Medicine Physician, Psychiatrist Senior Scientific Officer An agency of the European Union Disclaimer The views expressed
More informationPolypharmacology. Giulio Rastelli Molecular Modelling and Drug Design Lab
Polypharmacology Giulio Rastelli Molecular Modelling and Drug Design Lab www.mmddlab.unimore.it Dipartimento di Scienze della Vita Università di Modena e Reggio Emilia giulio.rastelli@unimore.it Magic
More informationPTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders. March 2018
PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders March 2018 Mar-18 Page 1 Forward looking statements within the meaning of The Private Securities Litigation
More informationINTERIM RESULTS AS OF MARCH 31, 2017
INTERIM RESULTS AS OF MARCH 31, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationConference call transcript for the March 2017 Quarterly Report
ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript
More informationPhase 1 SMA Type 2 Trial Initiation and Study Design. December 2017
Phase 1 SMA Type 2 Trial Initiation and Study Design December 2017 Disclaimers This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical
More informationImmuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma
Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma Stanley R. Frankel, MD, FACP Corporate Vice President, Clinical R & D Head, Immuno-Oncology Celgene Cancer Progress
More informationInvestor Update. Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Investor Update Basel, 1 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III
More informationDiscovery of Orally Bioavailable Small Molecules for Inhibition of Complement C5
Discovery of Orally Bioavailable Small Molecules for Inhibition of Complement C5 22 nd Congress of the European Hematology Association Madrid, Spain June 24, 2017 Forward Looking Statements This presentation
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationAddressing challenges of targeting the macrophage checkpoint, CD47. Marie Kosco-Vilbois, PhD CSO
Addressing challenges of targeting the macrophage checkpoint, CD47 Marie Kosco-Vilbois, PhD CSO 1 CD47 is an immune checkpoint Cancer cell Macrophage Activating eat me signal CD47 Inhibitory don t eat
More informationQuantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology Michael G Tovey, Director, Laboratory of Viral Oncology, Institut André Lwoff, Villejuif,
More informationSelecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update
Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update August 11, 2017 7:00 AM ET Positive Data from Ongoing Phase 2 Study of SEL-212 Reported at Clinical Meetings
More informationFebruary 28, Churchill Place Canary Wharf London E14 5EU United Kingdom
February 28, 2017 Submission of comments on 'Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products' (EMEA/CHMP/SWP/28367/07
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationMinutes of IND Committee meeting held on at ICMR (HQ), V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi.
Minutes of IND Committee meeting held on 24.10.2017 at ICMR (HQ), V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi. List of Participants: 1. Dr. Soumya Swaminathan, Secretary, Department of Health Research
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 16 June 2005 EMEA/CHMP/94526/2005 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) ANNEX GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
More informationBL-7040: Oligonucleotide for Inflammatory Bowel Disease
BL-7040: Oligonucleotide for Inflammatory Bowel Disease December 2012 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects,"
More informationPolatuzumab vedotin A potent ADC in NHL
Polatuzumab vedotin A potent ADC in NHL Michael Wenger, M.D. Senior Group Medical Director This presentation contains certain forward-looking statements. These forward-looking statements may be identified
More informationInvestor Presentation Stellar Biotechnologies, Inc. Nasdaq: SBOT. February 7, 2018
Investor Presentation Stellar Biotechnologies, Inc. Nasdaq: SBOT February 7, 2018 Safe Harbor This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities
More informationPK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis
More informationDrug Discovery Pipeline Overview 2011
Guangzhou Institutes of Drug Discovery Pipeline Overview 2011 1 Goal of the Pipeline Guangzhou Institutes of Mission: Capture the best ideas from the 3 scientific institutes at GIBH and translate the ideas
More informationResults FY2017 & Outlook 2018
March 13, 2018 Results FY2017 & Outlook 2018 MorphoSys AG Today on the Call Dr. Simon Moroney Jens Holstein Dr. Malte Peters Chief Executive Officer Chief Financial Officer Chief Development Officer 2
More informationAMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS (CARFILZOMIB) FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
January 29, 2015 ONO PHARMACEUTICAL CO., LTD. Corporate Communications public_relations@ono.co.jp AMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS Amgen (NASDAQ:AMGN) and its subsidiary Onyx
More informationFlow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity
Flow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity Michele Romano, PhD Product Manager Flow CAST is for Research Use Only. Not for use in diagnostic procedures.
More informationDeveloping innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO
Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of
More informationMomenta Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017 Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results --Company reports Glatopa 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the
More informationAssessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells
Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells David M, Hambly, Ph.D. Director, Analytical Development April 4th, 2016 Forward Looking Statements/Safe
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationJefferies 2017 Healthcare Conference
Jefferies 2017 Healthcare Conference June 9, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationRecombinant Biglycan for the Treatment! of Duchenne Muscular Dystrophy!!! PPMD Annual Conference, Jun 2013! By Joel B. Braunstein, MD!
Recombinant Biglycan for the Treatment! of Duchenne Muscular Dystrophy!!! PPMD Annual Conference, Jun 2013! By Joel B. Braunstein, MD! Tivorsan Overview Commercial operations began in 2010 around biglycan
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationataluren overview A New Approach to Genetic Disorders
ataluren overview A New Approach to Genetic Disorders Ataluren Scientific Background What is ataluren? Ataluren(formerly PTC124) is the first investigational therapy with the potential to enable the formation
More informationPreclinical to Clinical Translation of Antibody Drug Conjugates
Preclinical to Clinical Translation of Antibody Drug Conjugates Robert Lutz, PhD Crescendo Biopharma Consulting World ADC Summit Berlin 2016 1 Bio ImmunoGen 23 years Researcher in cell death and survival
More informationIdorsia Company Profile
Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has
More information